Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 17/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434200 | 0.92 | ALDH2 (0.54) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2107596 | 0.92 | ALDH2 (0.54) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL30562191 | 0.92 | ALDH2 (0.54) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2107625 | 0.92 | ALDH2 (0.52) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2107287 | 0.90 | ALDH2 (0.53) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2109208 | 0.89 | ALDH2 (0.51) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2110736 | 0.89 | ALDH2 (0.49) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2110738 | 0.88 | ALDH2 (0.49) | ALDH2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL2108168 | 0.87 | ALDH2 (0.64) | ALDH2MAOAMAOB | |
| SCHEMBL2110415 | 0.87 | ALDH2 (0.53) | ALDH2MAOAMAOBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | claimed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | claimed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-8158810-B2 | ALDH-2 inhibitors in the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2254878-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | Gilead Palo Alto, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009094028-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | disclosed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAOA 62/4885MAOB 47/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAOA 62/4885MAOB 47/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 4/4885MAOA 62/4885MAOB 45/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | ALDH2 1/4885MAOA 59/4885MAOB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.